NRG
NRG PALLAS is a Dutch nuclear research organization that produces medical isotopes (Mo-99, Lu-177, Pb-212) from its High Flux Reactor and delivers nuclear energy services to reactor operators, healthcare institutions, and new-build programs, including SMRs and advanced reactors.
- Company typePrivate
- Founded1998
- HeadquartersPetten, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What NRG does
NRG PALLAS B.V. is a Dutch nuclear research and services organization founded in 1998, headquartered in Petten, Netherlands, with offices in Arnhem and Alkmaar. The company operates the High Flux Reactor (HFR), one of the world's primary production reactors for medical isotopes, and is constructing the PALLAS reactor to replace HFR and secure future global supply. Its product portfolio spans five radioisotopes (Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192), two radiochemicals (Lutetium-177 n.c.a., Lead-212), and a comprehensive nuclear energy services offering covering in-service inspections, licensing, safety analyses, long-term operation support, fuel management, waste management, new-build program support, and SMR/advanced reactor development.
NRG PALLAS generates revenue through three streams: medical isotope sales to hospitals, cancer treatment centers, and pharmaceutical companies; professional nuclear energy services delivered directly to reactor operators and new-build programs; and training delivered through the NRG PALLAS Academy (radiation protection, RPO certification, refresher courses). The go-to-market is enterprise B2B with direct engagement of healthcare institutions (e.g., Netherlands Cancer Institute) and nuclear operators; pricing is not publicly disclosed and is contracted individually. The company supports 30,000 patients daily with its isotopes and distributes globally, with 101-250 employees operating under Dutch and international nuclear regulatory frameworks.
Recent strategic activity centers on the Lead-212 targeted alpha therapy partnership with TAG1 Inc. (April 2026), participation in the Lead4Life Initiative, the FCC agreement for PALLAS hot cells, formal expansion into SMR/advanced reactor services, and continued multi-hundred-million-euro construction of the PALLAS reactor. Research initiatives ILLUMINATE and SECURE advance nuclear medicine innovation, while the ReGuard radiation protection product and Patient Dosimetry services extend the supporting-services footprint. Ownership appears to be Dutch state-affiliated, with no disclosed venture capital or external funding rounds.
NRG firmographics
Firmographics- Name
- NRG
- Legal name
- NRG PALLAS B.V.
- Website
- https://nrg.eu
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NRG PALLAS is a Dutch nuclear research organization that produces medical isotopes (Mo-99, Lu-177, Pb-212) from its High Flux Reactor and delivers nuclear energy services to reactor operators, healthcare institutions, and new-build programs, including SMRs and advanced reactors.
- Ownership category
- akta.pro rank
NRG industry classification
Industry- Product category
- Nuclear Technology Services
- NAICS
- Testing Laboratories and Services (54138)
- SIC
- Hazardous Waste Management (4955), Instruments For Meas & Testing Of Electricity & Elec Signals (3825), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)
- akta.pro secondary industries
- Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis) (EUAKAIAL), Sealed Source Manufacturing, Encapsulation & Recycling/Take-Back (Source lifecycle management) (EUAKAIAI), Radiation Protection & Health Physics (ALARA, Dosimetry, Contamination Control) (EUAKABAH), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)
Keywords
Where NRG is headquartered
LocationHeadquarters
- HQ city
- Petten
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
NRG business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Others
Revenue model
- Medical Isotope Sales: Production and sale of medical isotopes including Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192, and Lead-212 to healthcare providers, hospitals, and pharmaceutical companies for diagnostic imaging and cancer treatment applications.
- Nuclear Energy Services: Consulting and technical services for nuclear reactor operations including in-service inspections, licensing, safety analyses, long-term operation support, fuel management, and waste management. Services provided to existing reactor operators and new-build nuclear programs.
- Education and Training: NRG PALLAS Academy provides radiation protection and nuclear technology courses including Radiation Protection Expert training, RPO courses, and refresher mathematics courses for professionals in the nuclear industry.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
NRG product offering
Product offeringCore offering
NRG PALLAS irradiates materials in the High Flux Reactor (HFR) to produce medical radioisotopes and radiochemicals — including Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192, Lutetium-177 n.c.a., and Lead-212 — that are used in nuclear medicine for diagnostic imaging and cancer therapy. The organization also delivers a full portfolio of nuclear energy services for existing reactor operators (in-service inspections, licensing, safety analyses, long-term operation support, fuel management, waste management and decommissioning) and new-build programs (new-build support, SMR and advanced reactor development, fuels and materials irradiations). The NRG PALLAS Academy provides radiation protection and nuclear technology training and certification.
Product overview
NRG PALLAS is a Dutch nuclear technology organization offering a portfolio of medical isotope solutions and nuclear energy services. The core product offerings include five radioisotopes (Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192) and two radiochemicals (Lutetium-177 n.c.a., Lead-212) for medical applications, which are used to diagnose and treat diseases including cancer. Supporting these are comprehensive nuclear energy services for existing reactors (inspections, licensing, safety analyses, long-term operation, fuel management, waste management) and new reactor development (new-build programmes, SMR and advanced reactor support, fuels and materials irradiations). The organization is constructing the PALLAS Reactor to replace the High Flux Reactor (HFR), securing future global medical isotope supply. Additional offerings include the PALLAS Academy providing radiation protection training, and research initiatives (ILLUMINATE, SECURE) advancing nuclear medicine and energy technologies.
Differentiator
Problem solved
Functional benefit
Brands
- PALLAS Programme: Dedicated project organization responsible for the construction of the new PALLAS reactor and its supporting infrastructure in Petten, Netherlands.
- NRG PALLAS Academy
Products and services
- Molybdenum-99 Medical radioisotope used primarily for diagnostic imaging, particularly in SPECT scans of organs and tissues. Sold to healthcare institutions and radiopharmaceutical manufacturers.
- Lutetium-177 Therapeutic radioisotope used in nuclear medicine for targeted radionuclide therapy, including treatment of prostate cancer and neuroendocrine tumors. Supplied to institutions including the Netherlands Cancer Institute.
- Terbium-161 Radioisotope for diagnostic and therapeutic applications in nuclear medicine. Sold to healthcare providers and research organizations.
- Yttrium-90 Radioisotope used for therapeutic applications including radioembolization procedures and treatment of liver cancers. Sold to hospitals and cancer treatment centers.
- Iridium-192 Radioisotope primarily used in industrial radiography and brachytherapy for cancer treatment. Sold to healthcare providers and industrial users.
- Lutetium-177 n.c.a. (non-carrier-added) High-purity, non-carrier-added Lutetium-177 radiochemical for targeted radionuclide therapy with enhanced specific activity. Supplied to pharmaceutical companies and research institutions.
- Lead-212 Alpha-emitting radioisotope being developed for targeted alpha therapy in cancer treatment, produced via Radium-224 capabilities. Used in Lead-212-based radiopharmaceuticals.
- NRG PALLAS Academy Educational and training division offering courses in radiation protection and nuclear technology, including Radiation Protection Expert certifications, RPO courses, and refresher mathematics courses for nuclear industry professionals.
- Radiation Protection Services Expert services including operational support, laboratory services, measuring, monitoring, calibrations, and ReGuard radiation protection solutions for nuclear facilities and professionals.
- In-Service Inspections Inspection services for existing nuclear reactors ensuring safe and reliable operation. Delivered to nuclear power plant operators.
- Licensing Services Support services for nuclear facility licensing and regulatory compliance. Provided to nuclear operators and new-build programs.
- Safety Analyses Comprehensive safety analysis services for nuclear reactors and nuclear facilities. Provided to reactor operators and regulators.
- Long Term Operation Support Technical services supporting the extended operation of nuclear reactors beyond their original design life. Delivered to existing reactor operators.
- Fuel Management Services for managing the nuclear fuel cycle, including fuel loading, monitoring, and lifecycle management. Provided to nuclear reactor operators.
- Waste Management & Decommissioning Services for radioactive waste processing and nuclear facility decommissioning. Provided to reactor operators and facility owners.
- New-Build Programmes Support services for new nuclear reactor construction projects. Delivered to organizations developing new nuclear power plants.
- SMRs & Advanced Reactor Development Services supporting Small Modular Reactors (SMRs) and advanced reactor technologies development. Delivered to advanced reactor developers.
- Fuels & Materials Irradiations Irradiation testing and validation services for nuclear fuels and materials in reactor environments. Provided to nuclear technology developers and researchers.
- ReGuard Radiation protection solution offering monitoring and safety services for nuclear facilities. Provided to nuclear operators and healthcare institutions.
- Patient Dosimetry Dosimetry services for patients undergoing nuclear medicine treatments and diagnostic procedures. Provided to hospitals and nuclear medicine departments.
Companies that use NRG
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
NRG technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NRG partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- TAG1 Inc.coreTAG1 Inc. and NRG PALLAS announced a partnership to develop and supply Lead-212 (Pb-212) for cancer therapies across Europe. The collaboration combines TAG1's portable Lead-212 generator with NRG PALLAS' Radium-224 production capabilities to address supply challenges in the industry for targeted alpha therapy.
- FCC (Construcción y Auxiliar de Ferrocarriles)majorAgreement signed between NRG PALLAS and FCC for the supply and installation of hot cells for the new PALLAS reactor. Hot cells are shielded enclosures used for handling radioactive materials during isotope production.
- Netherlands Cancer Institute (Antoni van Leeuwenhoek Ziekenhuis)coreCollaboration with the Netherlands Cancer Institute in Amsterdam where medical isotopes supplied by NRG PALLAS are used for cancer treatment, including prostate cancer treatment with Lutetium-177.
- Lead4Life InitiativecoreThe Netherlands' Lead4Life initiative supports the broader effort to develop Lead-212-based radiopharmaceuticals for cancer treatment, working with NRG PALLAS and TAG1 to advance targeted alpha therapy.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
NRG competitors and assessment
Company assessmentDirect peers
- Studsvik: Swedish nuclear services company providing fuel and materials testing, consulting, and waste management services. Directly comparable to NRG PALLAS's nuclear energy services business (inspections, safety analyses, fuel management, decommissioning support).
- Canadian Nuclear Laboratories (CNL): Operates the Chalk River Laboratories site with nuclear research reactors and medical isotope production capabilities (historically the largest Mo-99 supplier). Closest North American analog to NRG PALLAS's research-reactor-driven isotope model.
- ANSTO (Australian Nuclear Science and Technology Organisation): Operates the OPAL research reactor producing Mo-99, Lu-177 and other medical isotopes for global supply. National nuclear research organization with a similar mandate to NRG PALLAS — isotope production, nuclear services, training — making it a strong functional peer.
- Curium Pharma: One of the world's largest nuclear medicine companies, producing Mo-99 and Lu-177 at its facilities in France, the Netherlands and the US. Direct competitor to NRG PALLAS in medical isotope manufacturing and global supply, with overlapping isotope portfolios.
- IBA (Ion Beam Applications): Belgian leader in radiopharmaceutical production and proton therapy, with a sizable radioisotope production business (Mo-99, Lu-177) and growing radiopharma CDMO services. Closely comparable in production technology, isotope mix and European hospital customer base.
- South African Nuclear Energy Corporation (Necsa): Operates the Safari-1 research reactor at Pelindaba producing Mo-99 and other medical isotopes for global supply. A national nuclear research entity with parallel isotope production and nuclear services mandate, comparable to NRG PALLAS's role in Europe.
Broad incumbents
- Framatome: Major French nuclear reactor and fuel cycle services provider with growing medical isotope initiatives (Lu-177 production plans). Overlaps with NRG PALLAS's nuclear energy services business and emerging isotope activities, but operates at much greater scale.
- Orano: French nuclear fuel cycle and services company with growing medical isotope operations (notably Lu-177 production at its MELOX plant). Larger and broader than NRG PALLAS, but competes in both nuclear services and emerging isotope supply.
Emerging players
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing and commercializing diagnostic and therapeutic agents (including Lu-177 and alpha therapy programs). A downstream customer and ecosystem participant for isotope suppliers like NRG PALLAS rather than a direct production competitor.
- Lantheus Holdings: US-based radiopharmaceutical company focused on diagnostic imaging agents (notably Mo-99/Tc-99m through its POINT Biologics subsidiary). A downstream customer in the isotope supply chain that competes with NRG PALLAS-adjacent imaging isotope revenues.
Market position
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
NRG social profiles
Digital presenceNRG financial estimates
Financial estimateRevenue estimate
Valuation estimate
NRG leadership team
Management profileNumber of profiles
NRG funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NRG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NRG
What does NRG do?
NRG PALLAS irradiates materials in the High Flux Reactor (HFR) to produce medical radioisotopes and radiochemicals — including Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192, Lutetium-177 n.c.a., and Lead-212 — that are used in nuclear medicine for diagnostic imaging and cancer therapy. The organization also delivers a full portfolio of nuclear energy services for existing reactor operators (in-service inspections, licensing, safety analyses, long-term operation support, fuel management, waste management and decommissioning) and new-build programs (new-build support, SMR and advanced reactor development, fuels and materials irradiations). The NRG PALLAS Academy provides radiation protection and nuclear technology training and certification.
Is NRG a public or private company?
NRG is a private company. It is classified as state government owned and is currently operating.
When was NRG founded?
NRG was founded in 1998. It employs 101 to 250 people.
Where is NRG based?
NRG is headquartered in Petten, Netherlands, in the Europe region.
How does NRG make money?
Three revenue lines are on record. Medical Isotope Sales are the primary driver. The others are nuclear Energy Services and education and Training.
Who are NRG's main competitors?
Direct peers on record are Studsvik, Canadian Nuclear Laboratories (CNL), ANSTO (Australian Nuclear Science and Technology Organisation), Curium Pharma, IBA (Ion Beam Applications) and South African Nuclear Energy Corporation (Necsa). Broad incumbents are Framatome and Orano. Emerging players are Telix Pharmaceuticals and Lantheus Holdings.
Does NRG have an API?
No public API is recorded for NRG.
What industry is NRG in?
NRG's product category is Nuclear Technology Services. Its primary akta.pro industry code is EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.), with a secondary code of EUAKAIAL, Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis). Its NAICS code is 54138 and its SIC code is 4955.